"Drug Makers Rush to Meet Demand Amid Concerns Over Catalent-Novo Deal Impact"

Novo Nordisk and Eli Lilly are racing to meet the high demand for their weight-loss drugs, Ozempic and Mounjaro, by investing heavily in manufacturing capacity. Novo Nordisk's unorthodox strategy involves acquiring Catalent, a contract manufacturer that serves the pharmaceutical industry, including Eli Lilly. Both companies are facing challenges in keeping up with demand, leading to customer frustration and shortages. The dueling medications, known as GLP-1 drugs, have the potential to become the biggest-selling class of all time, with annual sales projected to exceed $100 billion. Despite the manufacturing challenges, both companies are seeing significant financial success from their top-selling drugs.